Share This Author
Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
There is an urgent need to establish standard panels of HIV-1 reference strains for wide distribution and a lack of uniformity in target strains used by different investigators to assess cross-neutralization has made the comparison of vaccine-induced antibody responses difficult.
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
This work employed computation-guided, in vitro screening to engineer a germline-targeting gp120 outer domain immunogen that binds to multiple VRC01-class bNAbs and germline precursors, and elucidated germline binding crystallographically.
Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection
It is indicated that more than one pathway leads to the development of broad cross-reactive neutralizing antibodies during HIV infection and that the virus continuously escapes their action.
Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies
Eliminating key glycosylation sites on HIV envelope (Env) restores binding of the germline versions of known broadly neutralizing anti-Env antibodies.
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
This study examined whether sera from recovered and naïve donors, collected before and after immunizations with existing messenger RNA (mRNA) vaccines, could neutralize the Wuhan-Hu-1 and B.1.
Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1
- I. Mikell, D. Sather, S. Kalams, M. Altfeld, G. Alter, L. Stamatatos
- BiologyPLoS pathogens
- 1 January 2011
It is found that anti-HIV-1 cross-neutralizing antibody responses first become evident on average at 2.5 years and, in rare cases, as early as 1 year following infection.
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
The findings discussed here suggest that the natural NAb response to HIV-1 can inform future vaccine design and a concerted effort of structure-based vaccine design will help guide the development of improved antibody-based vaccines for HIV- 1.
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation
V2 Loop Glycosylation of the Human Immunodeficiency Virus Type 1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by…
It is reported that the asparagines located at the amino- and carboxy-terminal sites, as well as within the V2 loop of the SF162 envelope, are glycosylated during in vitro replication of this virus in human peripheral blood mononuclear cells.